scholarly journals Chronic Administration of 7,8-DHF Lessens the Depression-Like Behavior of Juvenile Mild Traumatic Brain Injury Treated Rats at Their Adult Age

Pharmaceutics ◽  
2021 ◽  
Vol 13 (12) ◽  
pp. 2169
Author(s):  
Shih-Te Yang ◽  
Hsiu-Yi Hung ◽  
Long-Sun Ro ◽  
Ming-Feng Liao ◽  
Tamara G. Amstislavskaya ◽  
...  

Traumatic brain injury (TBI) is a leading cause of mortality and morbidity among the global youth and commonly results in long-lasting sequelae, including paralysis, epilepsy, and a host of mental disorders such as major depressive disorder. Previous studies were mainly focused on severe TBI as it occurs in adults. This study explored the long-term adverse effect of mild TBI in juvenile animals (mTBI-J). Male Sprague Dawley rats received mTBI-J or sham treatment at six weeks old, then underwent behavioral, biochemical, and histological experiments three weeks later (at nine weeks old). TTC staining, H&E staining, and brain edema measurement were applied to evaluate the mTBI-J induced cerebral damage. The forced swimming test (FST) and sucrose preference test (SPT) were applied for measuring depression-like behavior. The locomotor activity test (LAT) was performed to examine mTBI-J treatment effects on motor function. After the behavioral experiments, the dorsal hippocampus (dHip) and ventral hippocampus (vHip) were dissected out for western blotting to examine the expression of brain-derived neurotrophic factor (BDNF) and tropomyosin receptor kinase B (TrkB). Finally, a TrkB agonist 7,8-DHF was injected intraperitoneally to evaluate its therapeutic effect on the mTBI-J induced behavioral abnormalities at the early adult age. Results showed that a mild brain edema occurred, but no significant neural damage was found in the mTBI-J treated animals. In addition, a significant increase of depression-like behaviors was observed in the mTBI-J treated animals; the FST revealed an increase in immobility, and a decrease in sucrose consumption was found in the mTBI-J treated animals. There were no differences observed in the total distance traveled of the LAT and the fall latency of the rotarod test. The hippocampal BDNF expression, but not the TrkB, were significantly reduced in mTBI-J, and the mTBI-J treatment-induced depression-like behavior was lessened after four weeks of 7,8-DHF administration. Collectively, these results indicate that even a mild juvenile TBI treatment that did not produce motor deficits or significant histological damage could have a long-term adverse effect that could be sustained to adulthood, which raises the depression-like behavior in the adult age. In addition, chronic administration of 7,8-DHF lessens the mTBI-J treatment-induced depression-like behaviors in adult rats. We suggest the potential usage of 7,8-DHF as a therapeutic agent for preventing the long-term adverse effect of mTBI-J.

2017 ◽  
Vol 2017 ◽  
pp. 1-9 ◽  
Author(s):  
Won-Woo Choi ◽  
Kyungjin Lee ◽  
Beom-Joon Lee ◽  
Seong-Uk Park ◽  
Jung-Mi Park ◽  
...  

Chunghyul-Dan (CHD) is the first choice agent for the prevention and treatment of stroke at the Kyung Hee Medical Hospital. To date, CHD has been reported to have beneficial effects on brain disease in animals and humans, along with antioxidative and anti-inflammatory effects. The aim of this study was to evaluate the pharmacological effects of CHD on a traumatic brain injury (TBI) mouse model to explore the possibility of CHD use in patients with TBI. The TBI mouse model was induced using the controlled cortical impact method. CHD was orally administered twice a day for 5 d after TBI induction; mice were assessed for brain damage, brain edema, blood-brain barrier (BBB) damage, motor deficits, and cognitive impairment. Treatment with CHD reduced brain damage seen on histological examination and improved motor and cognitive functions. However, CHD did not reduce brain edema and BBB damage. In conclusion, CHD could be a candidate agent in the treatment of patients with TBI. Further studies are needed to assess the exact mechanisms of the effects during the acute-subacute phase and pharmacological activity during the chronic-convalescent phase of TBI.


2020 ◽  
Author(s):  
Fatemeh Dehghanian ◽  
Zahra Soltani ◽  
Alireza Farsinejad ◽  
Elham Jafari ◽  
Hamideh Bashiri

Abstract In recent years, the use of mesenchymal stem cells as a novel approach in the treatment of neurodegenerative diseases including traumatic brain injury has been proposed. In this study, the effect of oral mucosal mesenchymal stem cells (OMSCs) on traumatic brain injury was evaluated in long-term. Animals were divided into 4 groups including sham, TBI, vehicle (Veh) and stem cell (SC). Brain damage was induced by the Marmarou’s method. The number of 2 × 106 OMSCs was intravenously injected 1 and 24 hours after the injury. Brain edema and pathological outcome were assessed at 24 hours and 21 days after the injury. Besides, long-term neurological, motor and cognitive outcomes were evaluated at days 3, 7, 14, and 21 after the injury. inflammation (P < 0.01), reduce axonal damage (P < 0.01, P < 0.05; respectively) and prevent microglia proliferation (P < 0.05, P < 0.01; respectively) at 24 h and 21 days after the injury. Neurological function improvement (P < 0.001), memory enhancement (P < 0.05), anxiety-like behavior reduction (P < 0.001) and motor function amelioration (P < 0.05, P < 0.001, P < 0.01, P < 0.05; respectively) at days of 3, 7, 14, 21 after the injury were observed in the treatment group. According to the results of this study, OMSCs administration after TBI reduced brain edema and inflammation, and improved neurologic, memory and motor impairments, and anxiety-like behavior in long-term. Therefore, OMSCs could be a promising and new treatment option for TBI in the future.


Author(s):  
Oscar D. Guillamondegui

Traumatic brain injury (TBI) is a serious epidemic in the United States. It affects patients of all ages, race, and socioeconomic status (SES). The current care of these patients typically manifests after sequelae have been identified after discharge from the hospital, long after the inciting event. The purpose of this article is to introduce the concept of identification and management of the TBI patient from the moment of injury through long-term care as a multidisciplinary approach. By promoting an awareness of the issues that develop around the acutely injured brain and linking them to long-term outcomes, the trauma team can initiate care early to alter the effect on the patient, family, and community. Hopefully, by describing the care afforded at a trauma center and by a multidisciplinary team, we can bring a better understanding to the armamentarium of methods utilized to treat the difficult population of TBI patients.


Author(s):  
Billy Irwin

Abstract Purpose: This article discusses impaired prosody production subsequent to traumatic brain injury (TBI). Prosody may affect naturalness and intelligibility of speech significantly, often for the long term, and TBI may result in a variety of impairments. Method: Intonation, rate, and stress production are discussed in terms of the perceptual, physiological, and acoustic characteristics associated with TBI. Results and Conclusions: All aspects of prosodic production are susceptible to the effects of damage resulting from TBI. There are commonly associated prosodic impairments; however, individual variations in specific aspects of prosody require detailed analysis.


Sign in / Sign up

Export Citation Format

Share Document